|
86 Companies |
|
137 Products |
|
137 Products |
|
85 Mechanisms of Action |
|
4 Trials |
|
2019 News |
|
| «12...28293031323334353637383940» |
- Trial completion: Risk Perception in Drug-Dependent Adults With and Without Schizophrenia (clinicaltrials.gov) - May 3, 2012
P=N/A, N=120, Completed, Sponsor: National Institute on Drug Abuse (NIDA)
Recruiting --> Completed
- haloperidol / Generic mfg., clozapine / Generic mfg.
Trial completion: TCRS: Treat Clozapine ( CLZ )-Resistant Schizophrenia Comparing CLZ + Haloperidol vs. CLZ + Electroconvulsive Therapy (ECT) (clinicaltrials.gov) - May 3, 2012
P=N/A, N=18, Completed, Sponsor: Khon Kaen University
Recruiting --> Completed Recruiting --> Completed
- Enrollment open: Web-Based Delivery of MOVE! to Veterans With Serious Mental Illness (SMI) (clinicaltrials.gov) - May 1, 2012
P=N/A, N=300, Recruiting, Sponsor: Department of Veterans Affairs
Recruiting --> Completed Not yet recruiting --> Recruiting
- Trial completion: Cognitive Therapy for Negative Symptoms and Functioning (clinicaltrials.gov) - May 1, 2012
P2, N=61, Completed, Sponsor: University of Pennsylvania
Not yet recruiting --> Recruiting Recruiting --> Completed
- paliperidone extended release / Generic mfg.
Enrollment change: POST: The Paliperidone ER Observational Study of Economic, Functional, and Clinical Outcomes in Patients With Schizophrenia (clinicaltrials.gov) - Apr 30, 2012
P4, N=43, Terminated, Sponsor: Ortho-McNeil Janssen Scientific Affairs, LLC
Recruiting --> Completed N=580 --> 43
- Trial completion: Measuring Smoking Behavior in People With Schizophrenia and Bipolar Disorder (clinicaltrials.gov) - Apr 30, 2012
P=N/A, N=276, Completed, Sponsor: University of Medicine and Dentistry New Jersey
N=580 --> 43 Recruiting --> Completed
- | PF-05180999 / Pfizer
Trial completion: A Study to Assess the Relative Bioavailability of a Modified-Release Formulation of PF-05180999 (clinicaltrials.gov) - Apr 28, 2012
P1, N=12, Completed, Sponsor: Pfizer
Recruiting --> Completed Active, not recruiting --> Completed
- simvastatin / Generic mfg.
Trial termination: ASSIST: Add-on Simvastatin in Schizophrenia Trial (clinicaltrials.gov) - Apr 26, 2012
P=N/A, N=23, Terminated, Sponsor: New York State Psychiatric Institute
Active, not recruiting --> Completed Recruiting --> Terminated; Enrollment was slower than anticipated by the investigators and the funding research foundation.
- Trial termination: Treatment of Negative Symptoms of Schizophrenia With Transcranial Magnetic Stimulation (TMS) (clinicaltrials.gov) - Apr 26, 2012
P2, N=14, Terminated, Sponsor: New York State Psychiatric Institute
Recruiting --> Terminated; Enrollment was slower than anticipated by the investigators and the funding research foundation. Recruiting --> Terminated; Unable to adequately recruit subjects.
- simvastatin / Generic mfg.
Enrollment change: ASSIST: Add-on Simvastatin in Schizophrenia Trial (clinicaltrials.gov) - Apr 26, 2012
P=N/A, N=23, Terminated, Sponsor: New York State Psychiatric Institute
Recruiting --> Terminated; Unable to adequately recruit subjects. N=80 --> 23
- Enrollment change: Treatment of Negative Symptoms of Schizophrenia With Transcranial Magnetic Stimulation (TMS) (clinicaltrials.gov) - Apr 26, 2012
P2, N=14, Terminated, Sponsor: New York State Psychiatric Institute
N=80 --> 23 N=29 --> 14
- Enrollment change, Adherence: Improving Medication Adherence Among People With Schizophrenia Through the Use of 2-way Pagers (clinicaltrials.gov) - Apr 25, 2012
P=N/A, N=58, Completed, Sponsor: North Shore Long Island Jewish Health System
N=29 --> 14 N=80 --> 58
- pimozide / Generic mfg., clozapine / Generic mfg.
Enrollment change: Efficacy of Pimozide Augmentation for Clozapine Partial Response (clinicaltrials.gov) - Apr 25, 2012
P2, N=29, Completed, Sponsor: Yale University
N=80 --> 58 N=60 --> 29
- ||| Abilify Maintena (aripiprazole extended release) / Otsuka, Lundbeck
Trial completion: Safety and Tolerability Trial of Aripiprazole IM Depot Treatment in Adult Subjects With Schizophrenia Stabilized on Oral Antipsychotics Other Than Aripiprazole (clinicaltrials.gov) - Apr 25, 2012
P1, N=60, Completed, Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.
N=60 --> 29 Recruiting --> Completed
- Trial completion: WREN: Smoking Abstinence and Lapse Effects in Smokers With Schizophrenia and Controls (clinicaltrials.gov) - Apr 25, 2012
P2, N=60, Completed, Sponsor: Brown University
Recruiting --> Completed Recruiting --> Completed
- Trial completion, Adherence: Improving Medication Adherence Among People With Schizophrenia Through the Use of 2-way Pagers (clinicaltrials.gov) - Apr 25, 2012
P=N/A, N=58, Completed, Sponsor: North Shore Long Island Jewish Health System
Recruiting --> Completed Active, not recruiting --> Completed
- pimozide / Generic mfg., clozapine / Generic mfg.
Trial completion: Efficacy of Pimozide Augmentation for Clozapine Partial Response (clinicaltrials.gov) - Apr 25, 2012
P2, N=29, Completed, Sponsor: Yale University
Active, not recruiting --> Completed Recruiting --> Completed
- | lithium carbonate ER / Generic mfg., divalproex sodium XR / Generic mfg., quetiapine / Generic mfg.
Enrollment change: Treatment of Mania Symptoms With Drug Therapy (clinicaltrials.gov) - Apr 24, 2012
P3, N=75, Completed, Sponsor: Palo Alto Institute for Research and Education, Inc
Recruiting --> Completed N=105 --> 75
- || New P3 trial: CHANGE -it is About Life (clinicaltrials.gov) - Apr 24, 2012
P3, N=450, Not yet recruiting, Sponsor: Mental Health Services in the Capital Region, Denmark
- Trial completion: PEER: Do Consumer Providers Enhance Recovery? (clinicaltrials.gov) - Apr 24, 2012
P=N/A, N=285, Completed, Sponsor: Department of Veterans Affairs
N=105 --> 75 Active, not recruiting --> Completed
- Enrollment open: Effects of rTMS on Cigarette Smoking and Cognition in Schizophrenia (clinicaltrials.gov) - Apr 23, 2012
P=N/A, N=50, Recruiting, Sponsor: Centre for Addiction and Mental Health
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- Risperdal Consta (risperidone depot formulation) / J&J
Trial termination: Study of Amantadine for Risperidone Consta or Paliperidone Treated Patients to Decrease Prolactin Elevation (clinicaltrials.gov) - Apr 22, 2012
P4, N=6, Terminated, Sponsor: David C. Henderson, MD
Not yet recruiting --> Recruiting Recruiting --> Terminated; The sponsor withdrew support due to slow accrual of eligible subjects.
- Enrollment change: Study of Vitamin D in the Severely Mentally Ill (clinicaltrials.gov) - Apr 22, 2012
P=N/A, N=40, Recruiting, Sponsor: Bronx Psychiatric Center
Recruiting --> Terminated; The sponsor withdrew support due to slow accrual of eligible subjects. N=20 --> 40
- Risperdal Consta (risperidone depot formulation) / J&J
Enrollment change: Study of Amantadine for Risperidone Consta or Paliperidone Treated Patients to Decrease Prolactin Elevation (clinicaltrials.gov) - Apr 22, 2012
P4, N=6, Terminated, Sponsor: David C. Henderson, MD
N=20 --> 40 N=72 --> 6
- Enrollment change: IMPACT: Reducing Weight Gain and Improving Metabolic Function in Children Being Treated With Antipsychotics (clinicaltrials.gov) - Apr 19, 2012
P4, N=132, Recruiting, Sponsor: Johns Hopkins University
N=72 --> 6 N=240 --> 132
- lorazepam / Generic mfg.
Trial completion: Effects of Pentazocine Versus Lorazepam on Manic Symptoms (clinicaltrials.gov) - Apr 19, 2012
P2, N=20, Completed, Sponsor: Mclean Hospital
N=240 --> 132 Active, not recruiting --> Completed
- Trial termination: An Open Trial of Cysteamine Treatment in Schizophrenia (clinicaltrials.gov) - Apr 18, 2012
P=N/A, N=4, Terminated, Sponsor: Georgia Regents University
Active, not recruiting --> Completed Recruiting --> Terminated; The study was stopped after 4 years of recruitment difficulties.
- Trial completion: Neuroimaging Studies of Neurophysiological Phenotypes in Schizophrenia (clinicaltrials.gov) - Apr 18, 2012
P=N/A, N=225, Completed, Sponsor: National Institute on Drug Abuse (NIDA)
Recruiting --> Terminated; The study was stopped after 4 years of recruitment difficulties. Recruiting --> Completed
- Disalcid (salsalate) / Bausch Health
New P4 trial: Salsalate as an Adjunctive Treatment for Patients With Schizophrenia (clinicaltrials.gov) - Apr 15, 2012
P4, N=15, Recruiting, Sponsor: University of Massachusetts, Worcester
- Enrollment change: A Double-Blind Placebo Controlled Trial of Repetitive Transcranial Magnetic Stimulation (rTMS) in the Treatment of Negative Symptoms in Schizophrenia (clinicaltrials.gov) - Apr 14, 2012
P=N/A, N=22, Completed, Sponsor: The Alfred
Recruiting --> Completed N=40 --> 22
- Trial completion: A Double-Blind Placebo Controlled Trial of Repetitive Transcranial Magnetic Stimulation (rTMS) in the Treatment of Negative Symptoms in Schizophrenia (clinicaltrials.gov) - Apr 14, 2012
P=N/A, N=22, Completed, Sponsor: The Alfred
N=40 --> 22 Recruiting --> Completed
- Trial initiation date: e-CAeSAR: Evaluation of a Cognitive Adaptive E-treatment in Schizophrenia-diagnosed Adults (clinicaltrials.gov) - Apr 12, 2012
P2, N=150, Recruiting, Sponsor: Cate Stasio
Recruiting --> Completed Initiation date: Nov 2011 --> Apr 2012
- Enrollment open: e-CAeSAR: Evaluation of a Cognitive Adaptive E-treatment in Schizophrenia-diagnosed Adults (clinicaltrials.gov) - Apr 12, 2012
P2, N=150, Recruiting, Sponsor: Cate Stasio
Initiation date: Nov 2011 --> Apr 2012 Not yet recruiting --> Recruiting
- ||||| paliperidone extended release / Generic mfg.
New P4 trial: Symptomatic Remission and Social Function in Participants Treated With Paliperidone Extended Release (ER) (clinicaltrials.gov) - Apr 11, 2012
P4, N=480, Completed, Sponsor: Johnson & Johnson Taiwan Ltd
- ||||| paliperidone extended release / Generic mfg.
New P4 trial: A Study to Evaluate Flexible Dose of Paliperidone Extended Release (ER) and Clinical Response in Participants With Schizophrenia (clinicaltrials.gov) - Apr 11, 2012
P4, N=353, Completed, Sponsor: Johnson & Johnson Taiwan Ltd
- bupropion sustained-release / Generic mfg.
New P4 trial: Extended Duration Nicotine Replacement Therapy and Bupropion in Smokers With Schizophrenia (clinicaltrials.gov) - Apr 9, 2012
P4, N=17, Completed, Sponsor: Massachusetts General Hospital
- New P1 trial: Social Cognitive Training for Psychosis: Treatment Development (clinicaltrials.gov) - Apr 9, 2012
P1, N=40, Not yet recruiting, Sponsor: Yale University
- | PF-05180999 / Pfizer
Trial completion: A Study Of The Safety, Tolerability And Pharmacokinetics Of Single Doses Of PF-05180999 In Healthy Adults (clinicaltrials.gov) - Apr 9, 2012
P1, N=29, Completed, Sponsor: Pfizer
Not yet recruiting --> Recruiting Recruiting --> Completed
- |||| PF-02545920 / Pfizer
Trial completion: An Inpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Treatment Of Acute Exacerbation Of Schizophrenia (clinicaltrials.gov) - Apr 8, 2012
P2, N=259, Completed, Sponsor: Pfizer
Recruiting --> Completed Recruiting --> Completed
- || raloxifene hydrochloride / Generic mfg.
New P3 trial: FSJD-RAL-2010: Raloxifene as an Adjuvant Treatment of the Negative Symptoms of Schizophrenia in Post-menopausal Women (clinicaltrials.gov) - Apr 5, 2012
P3, N=80, Recruiting, Sponsor: Fundaci
- || Rexulti (brexpiprazole) / Lundbeck, Otsuka
Enrollment change: Trial to Evaluate the Effects of OPC-34712 on QT/QTc in Subjects With Schizophrenia or Schizoaffective Disorder (clinicaltrials.gov) - Apr 2, 2012
P1, N=218, Completed, Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.
Recruiting --> Completed N=180 --> 218
- ||| Rexulti (brexpiprazole) / Lundbeck, Otsuka
Trial completion: Trial to Evaluate the Effects of OPC-34712 on QT/QTc in Subjects With Schizophrenia or Schizoaffective Disorder (clinicaltrials.gov) - Apr 2, 2012
P1, N=218, Completed, Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.
N=180 --> 218 Recruiting --> Completed
- ||||| lurasidone / Generic mfg.
New P4 trial: High Dose Lurasidone for Patients With Treatment Resistant Schizophrenia (clinicaltrials.gov) - Apr 1, 2012
P4, N=120, Recruiting, Sponsor: Northwestern University
- Trial completion: ADAPT: Effect of Antipsychotics on Appetite Regulation (clinicaltrials.gov) - Apr 1, 2012
P=N/A, N=45, Completed, Sponsor: University of North Carolina, Chapel Hill
Recruiting --> Completed Recruiting --> Completed
- | AMG 747 / Amgen
New P2 trial: 20110165: Study to Evaluate the Effect of AMG 747 on Schizophrenia Negative Symptoms (Study 165) (clinicaltrials.gov) - Mar 29, 2012
P2, N=111, Terminated, Sponsor: Amgen
- | AMG 747 / Amgen
New P2 trial: 20101299: Study to Evaluate the Effect of AMG 747 on Schizophrenia Negative Symptoms (clinicaltrials.gov) - Mar 29, 2012
P2, N=121, Terminated, Sponsor: Amgen
- AMG 579 / Amgen
New P1 trial: First-in-Human Study to Evaluate AMG 579 in Healthy Subjects and Patients With Stable Schizophrenia (clinicaltrials.gov) - Mar 29, 2012
P1, N=50, Terminated, Sponsor: Amgen
- | olanzapine / Generic mfg., clozapine / Generic mfg.
New P4 trial, Adverse events: Alleviating the Metabolic Side Effects of Antipsychotic Medications (clinicaltrials.gov) - Mar 28, 2012
P4, N=90, Recruiting, Sponsor: Baker IDI Heart and Diabetes Institute
- |||||||||| lurasidone / Generic mfg.
New P3 trial: A Twelve Week, Open Label Extension Study in Patients With Schizophrenia (clinicaltrials.gov) - Mar 27, 2012
P3, N=191, Completed, Sponsor: Sunovion
- Enrollment closed: Contingency Management of Psychostimulant Abuse in the Severely Mentally Ill (clinicaltrials.gov) - Mar 27, 2012
P=N/A, N=200, Active, not recruiting, Sponsor: University of Washington
Recruiting --> Completed Recruiting --> Active, not recruiting